Literature DB >> 25080953

Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature.

Murat Bilgin1, Ahmet Akyel2, Mehmet Doğan2, Hamza Sunman2, Ekrem Yeter2.   

Abstract

Kounis syndrome (KS) is characterized by concurrent acute coronary syndrome and allergic reaction, in which acute inflammatory mediators cause spasm and/or erosion and rupture of coronary atheromatous plaque. In this report, we remind clinicians to consider KS in patients who are subjected to allergenic substances and demonstrate acute chest pain. A 36-year-old woman had chest pain, severe dyspnea, hypotension, and symmetrical negative T waves on the anterior leads during electrocardiography approximately two hours after the use of clarithromycin. KS was considered as a possible diagnosis based on the presentation. Laboratory tests revealed an elevated level of troponin I, suggesting myocardial infarction, and an elevated level of serum tryptase level, suggesting an allergic reaction. The patient promptly underwent coronary angiography, which revealed only plaques in all main coronary arteries without any obstructive lesion. To the best of our knowledge, we report herein the first case in the literature describing an association between clarithromycin and KS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25080953     DOI: 10.5543/tkda.2014.92891

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  2 in total

1.  Kounis syndrome type I in a victim of cardiopulmonary arrest after hymenoptera sting.

Authors:  Nikolaos V Cholevas; Loukianos S Rallidis; Aglaia Staurothanasopoulou; Eumorfia Pagaki; Dimitrios Platogiannis
Journal:  J Cardiol Cases       Date:  2017-03-06

2.  Clarithromycin-induced Coronary Vasospasms Caused Acute Coronary Syndrome in a 19-year-old Male Patient.

Authors:  Masahiro Ishikura; Akihiro Endo; Takahiro Sakamoto; Junya Tanabe; Koichi Okazaki; Takeshi Ouchi; Nobuhide Watanabe; Kazuaki Tanabe
Journal:  Intern Med       Date:  2020-09-19       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.